This is for a friend invested28 Sep 2025 22:50
Cev,
I have managed to take a look. It reminds me of OBD (Oxford Biodynamics PLC) which had same blood test kit for early detection. Yours is Kidney disease, OBD was testicular cancer. Both FDA approved. Both patented in US, and both UK listed.
The potential of OBD, was why i bought at 14p, sold at 57p. I rebought at 31p a while later, and thats when the story turned sour and how I don't see a repeat here. I managed to hold to bottom, buy and catch a Rebound loss of 18%. I built an Extension from my previous buy/sell so im in no way feeling its unsuccessful.
But back to RENX. The problem with OBD wasnt the product it was Sales and at $680 a pop it barely moved 15 in 6 months. It missed many opportunities to get NHS validated, enter studies and inevitably their naivety and overconfidence in the product is why they failed.
RENX is an astounding $980, medicare reimbursement ready and looking back to 2024 was at Roughly 124 a quarter, to now of April 2025 1000 a quarter. And thats just a New York Market current. Now they have a new deal with MVP and their 700.000 on the book available patrons, it could easily grab another 1000 a quarter. And thats current.
So basic math, makes it roughly $2 million revenue a quarter and growing, both in sales and customer base area so its rapidly growing.
Only had around 323 million shares top of my head in circulation so its done well. Obviously warrants, or other bits that will have to be taking into account but on the bones of it this could really run and gather momentum but also have the revenue to run alongside s0 for that ill be buying in.
It can't be cheaper, $0.26 on the OTC listing so it has no concerns on delisting, reverse split etc.
Hope that helps, its a hour of my time its all a could rummage